GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Foundation Medicine Inc (NAS:FMI) » Definitions » Debt-to-Equity

Foundation Medicine (Foundation Medicine) Debt-to-Equity : -12.89 (As of Jun. 2018)


View and export this data going back to 2013. Start your Free Trial

What is Foundation Medicine Debt-to-Equity?

Foundation Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2018 was $0.0 Mil. Foundation Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2018 was $110.0 Mil. Foundation Medicine's Total Stockholders Equity for the quarter that ended in Jun. 2018 was $-8.5 Mil. Foundation Medicine's debt to equity for the quarter that ended in Jun. 2018 was -12.89.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Foundation Medicine's Debt-to-Equity or its related term are showing as below:

FMI's Debt-to-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.22
* Ranked among companies with meaningful Debt-to-Equity only.

Foundation Medicine Debt-to-Equity Historical Data

The historical data trend for Foundation Medicine's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foundation Medicine Debt-to-Equity Chart

Foundation Medicine Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Debt-to-Equity
Get a 7-Day Free Trial 0.01 - - - 1.90

Foundation Medicine Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.90 4.76 -12.89

Competitive Comparison of Foundation Medicine's Debt-to-Equity

For the Diagnostics & Research subindustry, Foundation Medicine's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Foundation Medicine's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Foundation Medicine's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Foundation Medicine's Debt-to-Equity falls into.


Foundation Medicine Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Foundation Medicine's Debt to Equity Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 60) / 31.668
=1.89

Foundation Medicine's Debt to Equity Ratio for the quarter that ended in Jun. 2018 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 110) / -8.536
=-12.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foundation Medicine  (NAS:FMI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Foundation Medicine Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Foundation Medicine's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Foundation Medicine (Foundation Medicine) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Foundation Medicine Inc (NAS:FMI) » Definitions » Debt-to-Equity
Comparable Companies
SYNH MIL:DIA GH BRKR SHSE:603658 SZSE:300676 PRAH CRL NEOG ICLR QDEL GHDX SHSE:603882 MYGN BSP:DASA3 XPAR:ERF MEDP NEO NVTA BEAT
Traded in Other Exchanges
N/A
Address
Website
http://www.foundationmedicine.com
Foundation Medicine Inc is a molecular diagnostics company that specializes in the evaluation and treatment of cancer. Its products provide genetic information about a patient's cancer that is used by physicians to inform clinical decisions and by biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine's core molecular information products include FoundationOne, for solid tumors, and FoundationOne Heme, for blood-based cancers and hematologic malignancies. The vast majority of the firm's revenue is generated within the United States.
Executives
Alexis Borisy director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 16TH FLOOR, CAMBRIDGE MA 02142
Vincent A. Miller officer: Chief Medical Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Jason Ryan officer: Chief Financial Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Troy Cox director, officer: President and CEO C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Robert W. Hesslein officer: SVP and General Counsel C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas Civik officer: Chief Commercial Officer C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Evan/ Fa Jones director C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Roche Finance Ltd director, 10 percent owner, other: See footnote (1) C/O HOFFMAN LA ROCHE, 124 GRENSACHERSTRASSE CH 4002, BASEL SWITZERLAND V8
Roche Holding Ltd director, 10 percent owner, other: See footnote (1) ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Robert I Tepper 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Mark J Levin 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Third Rock Ventures Gp, L.p. 10 percent owner C/O THIRD ROCK VENTURES, 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116